Company profile
Pathfinder Cell Therapy, Inc.
OTC: PFND · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ 23GM —SS 35
v0.1 · 25/100 weight · pillars only
↑ listing tenure, growth stability · ↓ workforce scale, revenue growth (YoY)
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$1.4M
Employees
1
as of 2026-08-28
Market cap
$66.7k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02014
Net income-$1.4M-$1.4M2014
Operating income-$1.1M-$1.1M2014
Total assets$106.0k$106.0k2014
Equity-$5.9M-$5.9M2014
Revenue trend
FY2011 – FY2014 · USD
FY11
FY11
FY12
FY13
FY14
Revenue by segment
Filed disclosures · FY2013
By product
Russian Federation90%
Other Countries10%
By geography
Mts Czech Republic37%
Brazil30%
Hong Kong22%
Other Countries11%
The read
What is Pathfinder Cell Therapy, Inc.’s revenue?
Pathfinder Cell Therapy, Inc. booked $0 in FY2014 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
ProtoKinetix, Incorporated——Wellstar International, Inc.——Wesana Health Holdings Inc.——Biome Grow Inc.——Street Capital Inc.17DManhattan Scientifics, Inc.——Neighbors
Middlesex →Key facts
CEORichard L. Franklin
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeOTC: PFND
Employees1
IPO date2000-01-03
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.